Immuron Limited (IMRN)
Stock Price:
$7.21 USD
-0.14 (-1.90%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
32.11M |
| Revenue (ttm) |
1.68M |
| Net Income (ttm) |
-4.63M |
| Shares Out |
4.45M |
| EPS (ttm) |
-0.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$7.21 |
| Previous Close |
$7.35 |
| Change ($) |
-0.14 |
| Change (%) |
-1.90% |
| Day's Open |
7.33 |
| Day's Range |
6.92 - 7.40 |
| Day's Volume |
43,791 |
| 52-Week Range |
1.55 - 28.99 |
More Stats
| Market Cap |
32.11M |
| Enterprise Value |
28.50M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
4.45M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.68 |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6,398 |
| Short Ratio |
0.10 |
| Short % of Float |
n/a |
| Beta |
2.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.10 |
| PB Ratio |
10.16 |
| Revenue |
1.68M |
| Operating Income |
-3.64M |
| Net Income |
-4.63M |
| Free Cash Flow |
-1.27M |
| Net Cash |
3.61M |
| Net Cash / Share |
0.81 |
| Gross Margin |
72.05% |
| Operating Margin |
-216.33% |
| Profit Margin |
-194.00% |
| FCF Margin |
-75.42% |
| ROA |
-24.70% |
| ROE |
-45.05% |
| ROIC |
-155.50% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
195
Current: $7.21
High
195
Target: 194.85
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | 2.39 | 1.84 | 1.40 | 1.00 | 1.00 | 0.98 |
| Revenue Growth | 29.55% | 31.99% | 39.47% | -0.13% | 2.17% | - |
| Gross Profit | 1.72 | 1.42 | 1.06 | 0.43 | 0.49 | 0.51 |
| Operating Income | -5.16 | -4.84 | -8.33 | -8.27 | -4.28 | -2.84 |
| Net Income | -4.63 | -3.01 | -6.80 | -7.07 | -2.69 | -2.50 |
| Shares Outstanding | 143 | 130 | 135 | 135 | - | - |
| Earnings Per Share | -1.28 | -0.90 | -2.56 | -3.70 | -1.44 | -2.38 |
| Operating Cash Flow | -1.80 | -3.50 | -6.94 | -5.16 | -3.02 | -2.65 |
| Capital Expenditures | - | -0.01 | -0.01 | - | - | -0.02 |
| Free Cash Flow | -1.80 | -3.51 | -6.95 | -5.16 | -3.02 | -2.67 |
| Cash & Equivalents | 5.12 | 4.73 | 3.99 | 2.29 | 3.12 | - |
| Total Debt | - | - | 0.37 | 1.90 | - | - |
| Net Cash / Debt | 5.12 | 4.73 | 3.63 | 0.39 | 3.12 | - |
| Assets | 8.56 | 9.24 | 8.29 | 8.83 | 6.02 | - |
| Liabilities | 1.21 | 0.80 | 1.71 | 3.89 | 1.21 | - |
| Book Value | 7.35 | 8.44 | 6.57 | 4.94 | 4.81 | - |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Immuron Limited |
| CEO |
Jerry Kanellos |
Stock Information
| Ticker Symbol |
IMRN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMRN |
Description
Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Blackburn North, Australia.